				U.S. Depa	rtment of State				B No. 1405-011 PIRATION DATE	3 E: XX/XX/XXXX
			TUBI	ERCULOS	SIS WOR	KSH	EET	ES		DEN: 15 MINUTES
	Photo	Surnames			Given Names			(Age	· · · ,
	1 11010									
		Birth Date (mm-dd-yy	уу)	Document Type		Documer	nt Number	C	ase or Alien	Number
		Mediated Immunity to Tub								
S	ee Tubercu	losis Technical Instructions,	when requi	red, perform one	type only.					
	TST D	Date applied (mm-dd-yyyy)								
	F	Results (mm)	<u>.</u>							
	IGRA E	Date drawn (mm-dd-yyyy)								
	F	Positive Negative			If IGRA perform Quantife		which test:			
	Ē	Indeterminate, Borderline	e, or Equivo	cal	T-Spot	eron				
2. CI	-	Indication (Mark all that ap	ply)			_				
		Ray not indicated	=	vn HIV infection		Цн	listory of Tub	erculosis		
	Age <u>></u> 15 Signs or	symptoms of tuberculosis	_	≥ 10 mm or IGRA ase Contact: TST		A positiv	'e		Date Che (mm-dd-y	st X-Ray Taken
3. CI	0	Findings (for radiologist t				, i poonir	-		(11111-00-9	<i>yyy)</i>
	Normal F	indings A	bnormal Fir	ndings <i>(Indicate c</i>		ing, marl	king all that a	pply in the i	tables below	()
	1 614 4	Suggests Tuberculosis)	Mar			nears and C	
		or consolidation markings suggestive of fibro	_	liliary findings iscrete linear opa	citv		k as Class E er on DS-20	-	Not Mark a ner on DS-2	
	Cavitary			iscrete nodule(s)	-	tion 🔲	Cardiac		Smooth pleural t	hickening (if at CPA, not effusion [do lateral
) or mass with poorly define	d 🔲 Ve	olume loss or retr	action		Musculoske	eletal 🛛 🗖	Diaphragmatic te	ograph or ultrasound])
	Pleural e	(such as tuberculoma) ffusion		regular thick pleu	al reaction		Other, spec Remarks	ify in 🗖 🛙		ed calcified pulmonary
		diastinal adenopathy		Other			Romano		Calcified lymph r	node(s)
Radi	ologist's Re	marks								
-	F	Radiologist's Name (Printed,		Radio	logist's Signatur	e (Requi	ired)	Date In	terpreted (m	m-dd-yyyy)
4. Sp		ars and Cultures Decision	•							
	_	ndicated -Applicant has no s v Normal or 'No specimens r	• • •					ormed)		
	_	Normal or 'No specimens r			-	-				
		indicated - Applicant has (M	ark all that a	apply):						
	_	s or symptoms of TB								
		t X-ray suggests TB vn HIV infection								
		of treatment cultures								
5. Sp	outum Sme	ars and Cultures Results								
[Date specimen obt			ecimen reported	ł	Positive	Negative]	
	Sputum	(mm-dd-yyyy)		(11	nm-dd-yyyy)		1 USILIVE	Negative	-	
	Smear Results	1.							1	
		3.							-	
			ainad	Doto one siter a	roported /mar-	ddynew			J 	
	Sputum	Date specimen obt (mm-dd-yyyy)		*Use as date	n reported (mm- e of exam on DS	иа-уууу) -2054	Positive	Negative	NTM	Contaminated
	Culture	1.								
	Results	2.								
		3.								

6. Tub	perculosis Classification
Apj app	plicants may have more than one TB Classification. However, they cannot be classified as both Class B1 TB and Class B2 TB. In addition, olicants cannot be classified as Class B3 TB, Contact Evaluation if they are Class A or Class B1 TB, Extrapulmonary.
	No TB Classification CXR not suggestive of tuberculosis, no tuberculosis signs or symptoms, no known HIV infection, TST or IGRA negative <i>(if performed)</i> , not a contact
	Class A Applicant has tuberculosis disease
	Class B1 TB, Pulmonary CXR suggests tuberculosis, or tuberculosis signs and symptoms, or known HIV infection and sputum smears and cultures are negative and not a clinically diagnosed case.
	Class B1 TB, Extrapulmonary Applicants with evidence of extrapulmonary tuberculosis. The anatomic site of infection should be documented.
	Anatomic Site of Disease No treatment Current treatment Completed treatment Started but did not finish extrapulmonary treatment
	Class B2 TB, LTBI Evaluation Applicants who have a tuberculin skin test \geq 10 mm or positive IGRA but otherwise have a negative evaluation for tuberculosis. Contacts with TST \geq 5 mm or positive IGRA should receive this classification (if they are not already Class B1 TB, Pulmonary).
	No LTBI treatment If treated, LTBI treatment: If treated, mark LTBI regimen: Current LTBI treatment LTBI treatment by panel physician Isoniazid Completed LTBI treatment LTBI treatment by non-panel physician Rifampin Started but did not finish LTBI treatment Dates of treatment to 3HP
	Class B3 TB, Contact Evaluation Given Line Context Stress Context
	No preventive treatment Window Prophylaxis Isoniazid Rifampin 3HP Other Dates of treatment to
	Source Case:
	Name
	Case or Alien Number, if known
	Relationship to Contact
	Date Contact Ended (mm-dd-yyyy)
	Type of Source Case TB (Mark only one and attach DST results) Pansusceptible TB MDR TB (resistant to at least INH and rifampin) Drug-resistant TB other than MDR TB Culture negative Culture results not available DST results not yet available
Rema	rks

istory of Class A		e followin	g is true (mark appropriate	ontion):				
			Class A TB by the panel phy					
			t the time of presentation fo		dical avaminativ	20		
_ Applicant was		eatment a	t the time of presentation to	n their med		חו		
low was the diagr	nosis made: 🔲 F	Positive la	boratory tests	Clinical dia	gnosis			
Diagnostic Ches	t Radiograph							
Facility perfo	orming chest radiog	raph:				-		
Date Radiog	raph obtained (mm	-dd-yyyy)	:		_			
Findings Presen	t							
Normal	or no findings suge	gestive of	tuberculosis	□ +	lilar/mediastina	al adenopat	hy	
	e or consolidation				Ailiary findings			
	ar marking suggest	ive of fibr	nsis		Discrete linear o	pacity		
_	y lesion			=	Discrete nodule		calcification	
		orbe dofin	ad marging (quah ag		/olume loss or		calonication	
tubercu		ony defin	ed margins (such as					
	effusion				rregular thick p	eural reacti	ion	
					Other			
Sputum Smear F	Results at Diagnosis	S						
	men obtained	Da	ate specimen reported					
	dd-yyyy)		(mm-dd-yyyy)	Positive	e Negative			
1.								
2.								
3.								
Souture Culture		io						
	Results at Diagnos men obtained	1	to aposimon reported					
	dd-yyyy)	Da	ate specimen reported (mm-dd-yyyy)	Positive	e Negative	NTM	Contaminate	d
1.								
2.								
3.								-
5.								
Drug Susceptibil	ity Test Results							
м	ethod of DST:		Date specimen obtai	ned	Date D	ST reporte	d	
101			(mm-dd-yyyy)		(mn	n-dd-yyyy)		
	Agar L	J						
	T	Drug			Susceptible	Res	sistant	
	Isoniazid							
Required for first-line DST	Rifampin Ethambutol							
Inst-Ine DOI	Pyrazinamide							
	Ethionamide							
Required for	Amikacin							
multidrug-	Capreomycin							
resistant	Para-aminosalyci Fluoroquinolone,		PAS)					
cases		Specify.						
cases								
cases	Other, specify:							
cases								
cases								

Yes (mark all that apply):	1							
		acterium culosis		mpin stance		iazid stance		
Molecular Test	Positive	Negative	Positive	Negative	Positive	Negative		Second-Line Test
Hain Line Probe Assay								Performed, attach results
GeneXpert								
Other								
Treating physician or institutior Designated DOT site:	۱ 							
								_
Designated DOT site: Non-Designated DOT site		ge			Start Date	e (mm-dd-y	, , , , , , , , , , , , , , , , , , ,	End Date (mm-dd-yyyy)
Designated DOT site: Non-Designated DOT site Drug	:	ge			Start Date	e (mm-dd-y	<i>үууу)</i>	End Date (mm-dd-yyyy)
Designated DOT site: Non-Designated DOT site Drug soniazid	:	ge			Start Date	e (mm-dd-y	уууу)	End Date (mm-dd-yyyy)
Designated DOT site: Non-Designated DOT site Drug Isoniazid Rifampin Ethambutol	:	ge			Start Date	e (mm-dd-)	уууу)	End Date <i>(mm-dd-yyyy)</i>
Designated DOT site: Non-Designated DOT site Drug Isoniazid Rifampin Ethambutol	:	ge			Start Date	e (mm-dd-)	<i>үүуу)</i>	End Date (mm-dd-yyyy)
Designated DOT site: Non-Designated DOT site Drug Isoniazid Rifampin Ethambutol Pyrazinamide	:	ge			Start Date	e (mm-dd-y	<i>уууу)</i>	End Date (mm-dd-yyyy)
	:	ge			Start Date	e (mm-dd-)	<i>yyyy)</i>	End Date (mm-dd-yyyy)

PAPERWORK REDUCTION ACT AND CONFIDENTIALITY STATEMENTS

PAPERWORK REDUCTION ACT STATEMENT

Public reporting burden for this collection of information is estimated to average 15 minutes per response, including time required for searching existing data sources, gathering the necessary documentation, providing the information and/or documents required, and reviewing the final collection. You do not have to supply this information unless this collection displays a currently valid OMB control number. If you have comments on the accuracy of this burden estimate and/or recommendations for reducing it, please send them to: PRA_BurdenComments@state.gov

CONFIDENTIALITY STATEMENT

INA Section 222(f) provides that visa issuance and refusal records shall be considered confidential and shall be used only for the formulation, amendment, administration, or enforcement of the immigration, nationality, and other laws of the United States. The U.S. Department of State uses the information provided on this form to determine an individual's eligibility for a U.S. visa. Certified copies of visa records may be made available to a court which certifies that the information contained in such records is needed in a case pending before the court. The information provided may also be released to federal agencies for law enforcement, counterterrorism and homeland security purposes; to Congress and courts within their sphere of jurisdiction; and to other federal agencies who may need the information to administer or enforce U.S. laws. Although furnishing this information is voluntary, individuals who fail to submit this form or who do not provide all the requested information may be denied a U.S. visa or experience processing delays.

DS-3030

Page 4 of 4